Needham & Company Raises Price Target on 8x8, Inc. (EGHT) to $17 Following 1Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Needham & Company Raises Price Target on 8x8, Inc. (EGHT) to $17 Following 1Q Report
July 21, 2016 5:59 PM EDT
Today's After-Hours Movers
Puma Biotechnology, Inc. (NYSE: PBYI) 18.8% HIGHER; submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin®)-based therapy. Also, announced updated results from the Phase III clinical trial of Pumas investigational drug PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer (ExteNET trial). The ExteNET trial is a... More
July 21, 2016 4:15 PM EDT
8x8, Inc. (NASDAQ: EGHT) reported Q1 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60 million versus the consensus estimate of $57.87 million.
8x8, Inc. reaffirmed FY2016 guidance.
For earnings history and earnings-related data on 8x8, Inc. (EGHT) click here.
...
More
July 20, 2016 2:39 PM EDT
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Initial Claims - Street sees 265kContinuing Claims - no Street consensusPhiladelphia Fed - Street sees 5.0
9:00am EDT
FHFA Housing Price Index - no Street consensus
Earnings:
ABB Ltd. (NYSE: ABB) - consensus EPS $0.26
Adeptus Health (NYSE: ADPT) - consensus EPS $0.51
Alaska Air Group (NYSE: ALK) - consensus EPS $2.07... More
